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Innate lymphoid cells (ILCs) are innate immune cells that provide an early source of cytokines to initiate and tailor the immune response to the type of the encountered pathogen
or insult. The group 1 ILCs are comprised of conventional natural killer (cNK) cells and
subsets of “unconventional NK cells,” termed ILC1s. Although cNK cells and ILC1s
share many features, such as certain phenotypic markers and the ability to produce
IFN-γ upon activation, it is now becoming apparent that these two subsets develop from
different progenitors and show unique tissue distribution and functional characteristics.
Recent studies have aimed at elucidating the individual contributions of cNK cells and
ILC1s during protective host responses as well as during chronic inflammation. This
review provides an overview of the current knowledge of the developmental origins as
well as of the phenotypic and functional characteristics of ILC1s.
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INTRODUCTION
Innate lymphoid cells (ILCs) are a recently identified group of cells of the innate immune system that
modulate immune functions prior to the generation of an adaptive immune response. Unlike T cells
and B cells, ILCs lack antigen-specific receptors; instead, their function is mediated by cytokines
released by antigen-presenting cells or damaged tissue cells in response to infection or tissue damage.
Activated ILCs secrete cytokines that tailor the immune response to the encountered pathogen or
insult. Based on their secreted cytokine profile, ILCs are regarded as the innate equivalent of adaptive
T cells: group 1 ILCs are equivalent to Th1 T cells, group 2 ILCs to Th2 T cells, and group 3 ILCs
to Th17 and Th22 cells (1–4). The group 1 ILCs are comprised of conventional natural killer (cNK)
cells and several groups of “unconventional NK cells,” termed ILC1s, which differ from conventional
NK cells in their phenotypes, locations, functions, and/or transcription factor dependence. Within
group 1 ILCs, cNK cells appear to be more potent in mediating cytotoxicity (“killer ILCs”), while
the primary role of ILC1s is the production of pro-inflammatory cytokines (“helper-like ILCs”)
(2). This review will briefly touch on the key features of conventional NK cells as the prototype of
group 1 ILCs and will then discuss in more detail the known characteristics of the “unconventional
NK cells,” referred to here as ILC1s. Several subsets of ILC1s have been identified, which are located
predominantly within non-lymphoid tissues, such as the intestinal mucosa, liver, salivary gland, and
in the female reproductive tract. For some of the ILC1 subsets, a clear lineage relationship to ILC1s or
cNK cells has not firmly been established. The paucity of specific surface markers and transcription
factors for ILC1s has made studying these cells difficult. The ILC field in general is a relatively young
field of study, and within this field, group 1 ILCs are the least-well studied ILCs compared to ILC2s
and ILC3s. This review aims at giving an overview of the current knowledge on the phenotype and
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developmental origin of ILC1 subsets, as well as their roles during
antimicrobial immune defense and chronic inflammation.

elimination of altered host cells contributes to antiviral immunity
and tumor immunosurveillance (6–10). In humans, two main
cNK cell subsets exist that differ in their phenotype and functions: the majority of blood cNK cells are CD56low and display
high cytotoxic potential, while the minor CD56high subset of cNK
cells has low cytotoxic functions but shows potent production
of inflammatory cytokines (10, 11). In contrast to the peripheral
blood compartment, CD56high cNK cells represent the major
cNK cell subset within human secondary lymphoid tissues such
as lymph nodes, tonsils, and spleen (12). In mice, a subset of
cNK cells with thymic origin and preferential homing to lymph
nodes has been identified that may represent the equivalent of
human CD56high cNK cells (13). The lineage relationships and
specific functions of these different cNK cell subsets during host–
responses are still being investigated. Blurring the lines between
innate and adaptive lymphocytes, there is accumulating evidence
that demonstrates close parallels between cNK cells and adaptive
lymphocytes. Similar to T cells, cNK cells can undergo an expansion and contraction phase during microbial infections, followed
by the generation of a pool of memory cells. These memory cNK
cells possess enhanced cytolytic and cytokine responses during
secondary exposure to certain microbial pathogens, a finding that
suggests that immunological memory is not confined to adaptive
lymphocytes (14).

HETEROGENEITY WITHIN GROUP 1
ILCs: LOCATION, PHENOTYPE, AND
FUNCTIONS
The unifying characteristic of group 1 ILCs is their ability to
produce IFN-γ. Apart from this common attribute, significant
differences exist between the known ILC1 subsets. The following
sections summarize the current knowledge of the tissue location,
surface marker expression, and functional characteristics of the
main group 1 ILC subsets.

Conventional NK Cells

Conventional NK cells are predominantly found as circulating
in the blood and within secondary lymphoid tissues such as the
lymph nodes and spleen. However, cNK cells are also present in
some non-lymphoid tissues such as the liver and the lung. Resting
mature cNK cells are identified as CD3ϵ− NK1.1+ NKp46+ DX5
(CD49b)+ lymphocytes in the mouse (Table 1) and as CD3ϵ−
CD56+ NKp46+ NKp44− cells in humans (Table 2) (5, 6). Mature
cNK cells express the transcription factors T-bet and Eomes,
which are important in mediating their functions. cNK cells can
be activated through cytokines, such as IL-12, IL-15, and IL-18,
which induces their secretion of IFN-γ and TNF-α. Furthermore,
cNK cells are activated through ligation of specific surface receptors. cNK cells express a variety of activating and inhibitory
NK cell receptors that allow them to differentiate between self
and non-self and between healthy and infected or malignantly
transformed cells. Activation of cNK cells through these surface
receptors typically triggers cytokine production and can induce
cytotoxicity of target cells via cNK cell release of perforin and
granzymes. Through these functions, cNK cells fulfill a potent
pro-inflammatory role during the host–response to microbial
pathogens. In particular, cNK cell-mediated recognition and

ILC1s

Unconventional NK cells (ILC1s) are currently defined as tissueresident NK-like cells that do not develop from conventional
NK cell precursors (NKP) and are not typically found in blood
or lymphoid organs. Subsets of ILC1s have been identified in
a variety of non-lymphoid tissues, including small intestinal
mucosa, liver, salivary glands, and the female reproductive tract
(Tables 1 and 2). In mice, these pools of tissue-resident ILC1s
do not recirculate and appear to be maintained predominantly
via local self-renewal rather than through replenishment from
blood-derived ILC1s or their precursors (15–17). Apart from
these common attributes, significant differences exist between

TABLE 1 | Surface marker and transcription factor expression by murine group 1 ILCs.
NK1.1

NKp46

DX5

TRAIL

CD49a

CD160

CD127

CD11b

CD69

CXCR6

T-bet

Eomes

+
+
+
+
+
+

+
+
+
+
+
+

+
–
–
–
+
–

–
n.d.
+
+
+
–

–
+
+
+
+
+

–
+
+
+
n.d.
n.d.

–
+
±
±
–
–

+
–
–
–
+
n.d.

–
+
+
+
+
+

–
±
±
±
n.d.
n.d.

+
+
+
+
+
+

+
–
+
–
+
±

(6, 17, 25, 37, 45, 47, 59)
(20, 30, 45, 47)
(2, 19, 45, 47)
(16, 17, 20, 25, 26, 45, 47)
(34, 35, 36)
(17, 37, 40)

Eomes Reference

Splenic cNK
LP ILC1
ieILC1
Liver ILC1
Salivary ILC1
Uterine ILC1

Reference

±, heterogenous expression; n.d., not determined.

TABLE 2 | Surface marker and transcription factor expression by human group 1 ILCs.

Blood cNK (CD56low)
Blood cNK (CD56high)
LP ILC1
ieILC1
Liver ILC1

CD56

NKp46

+
+++
–
±
+++

+
+
–
+
+

NKp44 CD103 CD49a CD160 CD127
–
–
–
+
–

–
–
–
+
±

–
–
n.d.
+
±

–
–
+
+
n.d.

–
+
+
–
–

CD11b

CD69

CD16

CXCR6

T-bet

+++
+++
n.d.
–
n.d.

±
±
±
+
+

+++
–
–
–
–

–
–
n.d.
+
+

+
+
±
+
+

+
+
–
+
±

(2, 5, 10, 11, 31)
(2, 10, 11, 31)
(18, 24)
(19, 24)
(31, 32)

±, heterogenous expression; n.d., not determined.
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the individual ILC1 subsets in regards to their phenotype and
known functions. Furthermore, for some of these subsets, which
appear to be ILC1s based on their characteristic cytokine production, a clear lineage relationship to other ILC1s or cNK cells has
not firmly been established. For the purpose of this review, I will
focus on some of the better-characterized members of the ILC1
lineage, which includes the subsets of ILC1s in the intestine and
liver.

immature cNK cells (25), liver-resident ILC1s are now recognized
as a separate lineage of group 1 ILCs with different progenitor
origin, cell trafficking, and functional capacities than cNK cells
(26–28). Liver ILC1s are potent producers not only of IFN-γ but
also of additional cytokines such as TNF-α, IL-2, and GM-CSF.
Liver-resident ILC1s lack the typical cytotoxic machinery – perforin and granzymes A and B – that are common to cNK cells.
In contrast, they express high levels of granzyme C and display
potent TRAIL-mediated cytotoxicity (17, 29, 30). Human liver
ILC1s have been identified as CD56high CD16− cells capable of producing IFN-γ upon activation (31). While the majority of these
cells are CD49a− Eomes+, a minor subset expresses CD49a+ and
lacks Eomes, and may thus represent the human counterpart of
murine liver CD49a+ ILC1s (32). In mice, liver ILC1s are capable
of generating immunologic memory to haptens and viral antigens
and are capable of mediating robust recall responses upon rechallenge with the same antigen (16, 33), a feature that has not yet
been demonstrated for any of the other known ILC1 subsets.

Intestinal ILC1s

Intestinal ILCs that express typical NK cell receptors –NKp46 and
NK1.1 in the mouse; NKp46 and/or CD56 in humans – have in
the past collectively been considered as cNK cells due to their NK
cell-like phenotype and their ability to produce IFN-γ. However,
evidence is now emerging that the intestinal mucosa contains
several types of group 1 ILCs that are distinct from cNK cells. Two
main subsets of intestinal ILC1s were recently identified in mice
and humans: intraepithelial ILC1s (ieILC1s) and lamina propriaresident ILC1s (LP ILC1s) (18–20). ieILC1s are found in the
intestinal epithelium and resemble cNK cells in their expression
of canonical NK cell receptors. However, unlike resting cNK cells,
ieILC1s express surface markers typical of intraepithelial T cells,
such as the integrin CD49a, the activation marker CD69, the
HVEM receptor CD160, and in humans, the integrin CD103 (19).
To date, it is unclear whether this surface marker pattern is a result
of tissue factors encountered in the intestinal epithelium, or is a
characteristic of a separate lineage of cells. Like cNK cells, ieILC1s
express the transcription factors T-bet and Eomes; however, studies in mice provided evidence that ieILC1s do not develop from
a conventional NKP (discussed below in Section Development).
Like most other ILC1s, ieILC1s are potent producers of IFN-γ,
which they release in response to IL-12 and IL-15, and are likely
to contribute not only to immune protection but also to chronic
inflammation of the intestinal mucosa.
Murine LP ILC1s share characteristics with cNK cells and
ieILC1s, including surface expression of NKp46 and NK1.1.
However, unlike the latter two subsets, mouse LP ILC1s express
high levels of the IL-7 receptor alpha chain (CD127). Furthermore,
LP ILC1s are positive for CD27, Thy1, and c-kit, which are not
typically expressed on mature cNK cells, and they are negative for
most Ly49 receptors. Unlike cNK cells and ieILC1s, LP ILC1s only
express T-bet but not Eomes (20). In human intestinal lamina propria, a CD127+ ILC subset with ILC1-like functions has recently
been described. These cells lack CD56 and NKp46 but express
CD161, a marker also found on some human cNK cells, ILC2s,
and ILC3s (18, 21–23). These ILC1s are Eomes negative; subsets of
these cells are T-bet positive and produce IFN-γ (18, 24).

Salivary Gland ILC1s

In mice, a unique subset of NK-like cells resides in salivary glands
(34–36). While these cells closely resemble cNK cells in both surface receptor and transcription factor expression, they also share
several features with unconventional NK cells, and in particular,
with liver ILC1s. Most notably, both salivary gland ILC1s and liver
ILC1s express TRAIL and CD49a (34, 35). Unlike liver ILC1s;
however, salivary gland ILC1s express DX5 and Eomes. Salivary
gland ILC1s are similar to liver ILC1s in their ability to induce
TRAIL-mediated cytotoxicity; however, in contrast to most other
ILC1s, salivary gland ILC1s are poor producers of IFN-γ and thus
do not entirely fit the classical definition of group 1 ILCs (34, 36).

ILC1s in Other Tissues

NK-like cells are also found in other non-lymphoid organs,
such as the uterus, kidney, and skin of mice and humans (17,
37–41). These cells vary in their phenotype, transcription factor
expression, and functions, which may in part be dictated by their
specific tissue microenvironment. Common features of these
NK-like cells are their relatively poor cytotoxic potential but
potent production of cytokines and growth factors. In the pregnant uterus, non-classical NK cells are thought to play important
roles during fetal implantation and vascular remodeling at the
decidua (40–42). These uterine NK cells share features with cNK
cells, such as the expression of certain activating and inhibitory
NK cell receptors, and the expression of perforin and granzymes.
However, their developmental origin is still debated (40, 41). In
the uterus of virgin mice, several distinct cell populations with
NK-like (NK1.1+ NKp46+ T-bet+) phenotype were recently
described: DX5+ CD49a− cells that likely represent cNK cells as
well as a DX5− CD49a+ putative ILC1 population that contains
both Eomes+ and Eomes− subsets (17, 37). Further studies are
needed to investigate the lineage relationships of these distinct
uterine group 1 ILC subsets and their individual functions at this
tissue site. DX5− CD49a+ ILC1s with similarity to liver ILC1s were
also described in murine skin and kidneys (17, 38). In the murine
lung, cNK cells have been studied extensively (5); however, it is
currently unknown whether lung tissue also contains distinct

Liver ILC1s

The liver contains cNK cells as well as ILC1s, the two of which can
be distinguished by their different expression of surface markers
and transcription factors. In mice, liver ILC1s are CD3ϵ− NK1.1+
DX5− cells with high expression of both the integrin CD49a
(VLA-1) and the cytotoxicity-inducing ligand TRAIL. In contrast,
cNK cells in the liver are DX5+ CD49a− TRAIL−. Both cNK and
ILC1s in the liver express T-bet; however, like LP ILC1s, liver
ILC1s do not express Eomes. Originally believed to represent
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ILC1 subsets. In human lung, a putative ILC1 subset has recently
been identified (43); however, further studies are required to
confirm its specific phenotype and to investigate its functions.

tissues represent a relatively homogeneous population. Despite
the differences between individual ILC1 subsets, common signature genes were identified that distinguish ILC1s from cNK
cells; among these are higher transcript levels for CD127, the
chemokine receptor CXCR6, and, interestingly, for some T cell
receptor (TCR) chains, although no TCR chain protein expression was detected either intracellularly or on the cell surface. The
latter finding is intriguing as it suggests common transcriptional
programs between ILC1s and T cells.

ILC Plasticity

Further complicating the identification of ILC1s, a subset of
group 3 ILCs in murine intestinal tissues, termed NCR+ ILC3s, was
recently shown to convert to IFN-γ-producing, T-bet-expressing
cells during microbial infections (20, 21, 44). Conversion of these
ILC3s is accompanied by their downregulation of their specific
transcription factor RORγt, resulting in a cell population that
resembles ILC1s in their phenotype and cellular functions. Due
to their different lineage relationship compared to ILC1s, these
converted ILC3s, termed “ex-RORγt ILCs,” are not typically
regarded as a “true” ILC1 subset. Additional ILC plasticity was
recently identified for a subset of human tonsil ILC1s, which in
culture with ILC3-polarizing cytokines acquired RORγt expression and switched their cytokine profile from predominantly
IFN-γ to the ILC3-specific cytokine IL-22 (24). This conversion
was not seen in mice, as LP ILC1s were unable to convert to
ILC3s; however, “ex-RORγt ILCs” were capable of reverting back
to RORγt-expressing ILC3s (24).

DEVELOPMENT
All ILCs develop from a common lymphoid progenitor (CLP),
which further differentiates into a shared ILC precursor, termed
α-lymphoid precursor (αLP) (or common ILC progenitor, CILP).
This shared precursor can be identified by its expression of the
integrin α4β7 and of CD127. Further differentiation of αLP
generates at least two different precursors with more restricted
lineage repopulation capacity: a common helper ILC precursor
(CHILP) that can give rise to ILC1s and all other ILC subsets
except cNK cells, and an NKP, which can differentiate into cNK
cells but no other ILCs (2, 46–48) (Figure 1). Differentiation of
these precursors from CLP requires the acquisition of the transcription factors Id2, NFIL3, and Tox; mice deficient in any of
these factors show greatly reduced numbers of all ILCs (49–55).
Additionally, the Runx family of transcription factors and in
particular, Runx3 is required for normal development of group 1
and group 3 ILCs (56, 57). The development of mature ILC1s and
cNKs from CHILPs and NKP, respectively, depends on a variety
of additional transcription factors and cytokines, many of which
have only very recently been elucidated. The following sections
discuss the individual requirements for the differentiation of cNK
cells and ILC1s from these early precursors.

ILC1 Signature Genes

Transcriptional profiling of ILC1s and cNK cells from liver, small
intestine, and spleen recently demonstrated that the gene expression by these tissue ILC1s clearly differs from that of cNK cells.
Principle-component analysis from this study placed the tested
ILC1 subsets closer to each other than to cNK cells from the same
tissues. However, in addition to shared gene signature, each ILC1
subset possesses a tissue-specific transcriptional signature (45).
In contrast, liver and spleen cNK cell transcriptional profiles
were indistinguishable, indicating that cNK cells from different

FIGURE 1 | Development of ILCs. All ILCs develop from a common lymphoid progenitor (CLP), which differentiate into a committed ILC precursor population
(αLP). The development of cNK cells then diverges from that of other ILCs: cNK cells arise from an NK cell precursor (NKP), while all other ILCs are formed from a
common helper innate lymphoid precursor (CHILP) that upon upregulation of the transcription factors Id2, PLZF, and GATA-3 become committed innate lymphoid
cell precursors (ILCp) and can give rise to ILC1s, as well as to most group 2 and 3 ILCs. Development of mature cNK cells from NKPs is critically dependent on the
transcription factors Eomes but also involves T-bet, while ILC1 development from ILCp is dependent on T-bet but not Eomes.
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Development of cNK Cells

T-bet (17, 19, 20, 25, 62). In contrast to cNK cells, which require
Eomes for their final maturation, liver ILC1s and presumably all
other Eomes− ILC1s develop independently of this transcription
factor (25). Interestingly, there is remarkable diversity among
ILC1 subsets in relation to their dependence on other transcription factors and cytokines. Although NFIL3 is required for the
development of most group 1, 2, and 3 ILCs, including cNK cells
and intestinal ieILC1s, mice deficient in this transcription factor
have normal numbers of salivary gland, uterine, and kidneyresident ILC1s (17, 34, 38). In regards to liver ILC1s, the precise
role of NFIL3 remains to be determined, as currently conflicting
data exists showing either dependence (49, 55) or independence
of liver ILC1s on this transcription factor (17, 63). Similarly,
dependence on the transcription factor GATA-3 appears to vary
between the individual ILC1 subsets. GATA-3 deficiency severely
reduces numbers of intestinal LP ILC1s but has no effect on ieILC1
or cNK cell numbers (64). As development of all CD127+ group 2
and group 3 ILCs is dependent on GATA-3, it has been suggested
that only CD127+ ILC1s but not CD127− ILC1s require GATA-3
for their development (20, 64).
Development of most group 1 ILCs, including cNK cells,
is dependent on the cytokine IL-15. We recently found that in
contrast to all other ILC1s, intestinal ieILC1s were only partially
dependent on IL-15, as their numbers were reduced but not
absent in mice deficient in the IL-15 receptor alpha chain (19).
Although some ILC1 subsets express the IL-7 receptor CD127,
IL-7 appears dispensable for ILC1 development, as mice deficient
in IL-7 or its receptor CD127 have normal numbers of intestinal
LP and liver ILC1s (20, 26, 51).
The differences in transcription factor and cytokine requirements within ILC1s may be a result of different lineage relationships between these individual subsets. Further studies are
needed to identify the individual precursors and their location
(bone marrow vs. development in peripheral tissues) for each of
these ILC1 subsets and elucidate potential pathways of conversion within group 1 ILCs and potentially between other ILCs.

Direct precursors to cNK cells (NKP) were originally defined as
lineage-negative (Lin−) cells that express the IL-2 receptor beta
chain (CD122) but none of the typical NK cell receptors. This precursor population, however, was later found to include cells with
T cell differentiation potential and was subsequently refined to
include only Lin−CD122+ cells that co-expressed CD244, CD27,
and CD127. The generation of NKPs from CLPs is dependent
on the transcription factors NFIL3, Id2, and Tox, which are also
involved in the development of CHILPs for ILC development
(1, 2). Unlike other ILCs, however, development of cNK cells
does not include a precursor that expresses the transcription
factor PLZF. As recent studies demonstrated, PLZF is specifically
expressed during ILC differentiation from CHILPs, allowing a
further refinement of the differences between NKP and ILC1
precursors. PLZF lineage-tracing experiments revealed that true
NKPs have the phenotype Lin−CD122+CD244+CD27+CD127+PL
ZF−α4β7−, while ILC1 precursors are characterized by additional
expression of PLZF and α4β7 (58).
Further differentiation of NKPs gives rise to immature cNK
cells, a process that is accompanied by gradual acquisition of the
NK cell receptors NK1.1 and NKp46 and the transcription factors T-bet and Eomes. Immature cNK cells can be identified as
DX5− CD27+ CD11b− cells, which are T-bet+ but Eomes− (23, 25,
59). With these marker characteristics, immature cNK cells have
striking similarity to ILC1s, making it difficult to differentiate
between the two populations. Maturation of cNK cells is dependent on the cytokine IL-15 and is accompanied by the acquisition
of DX5, upregulation of CD11b, and loss of CD27 expression. The
cytokine IL-7, which is crucial for the development of group 2
and 3 ILCs, is not required for mature cNK cell or ILC1 development (20, 26, 51). cNK cell maturation is dependent on Eomes
and T-bet, as mature cNK cells are absent in Eomes-deficient
mice and reduced in numbers and with less mature phenotype in
T-bet-deficient mice (25, 60).

Development of ILC1s

It has been proposed that ILC1s, like group 2 and 3 ILCs, develop
from a CHILP that further differentiates into an ILC precursor
(ILCp) in a PLZF-dependent process (48, 58). Lineage tracing
for PLZF expression revealed that all ILCs, with the exception of
cNK cells and a subset of ILC3s (LTi-like ILC3s), develop from
a PLZF-positive precursor (48). Among the investigated group 1
ILCs, liver ILC1s and intestinal ieILC1s, but not splenic or liver
cNK cells, were lineage traced for PLZF expression, and thus,
the former two are likely to arise from the same ILC precursor
(48). Other ILC1s such as LP ILC1s or salivary gland ILC1s were
not interrogated in this study (48). Interestingly, PLZF-deficient
bone marrow can still generate normal numbers of ieILC1s (48),
indicating the existence of alternative pathways for ILC1 differentiation, which may involve branching from either PLZF− CHILP
or NKP. Within ILCp, the highest ILC1-generating capacity was
found in a CD122+ subset that lacks the chemokine receptor
CXCR5, suggesting that these CD122+ CXCR5+ ILCp may represent the direct precursors to ILC1s (61).
Differentiation of liver ILC1s and intestinal ILC1s (both LP
ILC1s and ieILC1s) further depends on the transcription factor
Frontiers in Immunology | www.frontiersin.org

ILC1s IN ANTIMICROBIAL RESPONSES
The prototypic function of group 1 ILCs is potent expression
of IFN-γ upon activation with cytokines or surface receptor
crosslinking. IFN-γ plays important roles in the immune defense
to intracellular pathogens, and cNK cells have been recognized
for their critical functions in the immune defense against a
variety of viral and bacterial pathogens (7, 9). In most of these
studies, all cells with NK-like surface phenotype and ability
for IFN-γ production were regarded as cNK cells. However, it
appears likely that in some of the earlier studies, ILC1s may have
contributed to IFN-γ production but were not recognized as a
separate lineage. Thus, specific roles of ILC1s, as compared to
cNK cells, during immune defenses to pathogens are only now
being investigated.
The identification of specific markers for ILC1s, such as CD49a
expression in liver or expression of CD127 and lack of Eomes in
LP ILC1s, has made it possible to more accurately assess specific
host protective roles of ILC1s compared to cNK cells. However, as
marker expression can change during cellular activation, results
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still need to be interpreted with caution. Recent studies have
 rotective
focused on the potential roles of intestinal ILC1s during p
responses to intestinal pathogens. New findings in this respect
suggest that following oral infection of mice with the intracellular pathogen Toxoplasma gondii, ILC1s produce the majority of
IFN-γ, as well as TNF-α, while cNK cells and ILC3s contribute to
a lesser extent (20). In this particular infection model, Diefenbach
and colleagues identified ILC1s as the cell type responsible for
controlling infection, which they accomplish by their rapid
attraction of inflammatory monocytes to the site of infection.
Unfortunately, due to the lack of specific ILC1-knockout mice or
depleting antibodies, it is currently impossible to unequivocally
attribute a particular function to either ILC1s or cNK cells. In the
mentioned study on host responses to T. gondii, Diefenbach and
colleagues examined T-bet-deficient mice, which completely lack
ILC1s but have cNK cells (although in reduced numbers), as a
tool to confirm a crucial role of ILC1s during T. gondii infection.
However, it should be noted that T-bet also plays roles in cNK
cell maturation and IFN-γ production (60); thus, the failure of
T-bet-deficient mice to control parasite burden may still partially
be due to defects in cNK cell functions. Additionally, T-bet is also
required for the development of NCR+ ILC3s and their conversion into IFN-γ-producing cells (65).
During acute infection with the intestinal pathogen Clostridium
difficile, ILC1s represent the major innate cell subset to respond
with IFN-γ production in the LP, epithelium, and MLN of
infected mice (66). Consistent with this finding, Pamer and colleagues further demonstrated that mice lacking ILC1s as well as
mice deficient in IFN-γ were more susceptible to lethal C. difficile
infection. For this study, T-bet-deficient mice on a Rag-deficient
background were used to deduct a specific role for ILC1s during
the immune defense, and adoptive transfer of T-bet+ CD127+
LP ILC1s to these mice imparted partial protection from lethal
infection. However, as ILC1 transfer only provided partial rescue,
the authors speculate that the contribution of other innate cells,
such as cNK cells, neutrophils and monocytes, is likely required
for protective IFN-γ responses to C. difficile (66).
IFN-γ is also a major factor in the immune defense to intestinal infections with Salmonella enterica serovar Typhimurium.
A recent study demonstrated that a group of lamina propria
ILCs was shown to provide the majority of IFN-γ during acute
infection. However, in this study, it was concluded that converted
ILC3s, rather than true ILC1s, were responsible for the majority
of the produced IFN-γ (65). As illustrated in the examples above,
there is emerging evidence that intestinal ILC1s contribute to the
immune defense to microbial pathogens. However, to date, an
accurate assessment of the individual roles of ILC1s, cNK cells,
and converted ILC3 remains impossible. Further exploration
of novel markers and transcription factors involved in ILC1
development and functions may aid in further elucidating their
specific roles during host protective responses.

However, exaggerated or prolonged cytokine responses can also
lead to chronic inflammation and autoimmunity. Several studies
demonstrated that inflamed intestinal tissues from patients with
Crohn’s disease harbor larger numbers of ILC1s, suggesting a
role for ILC1s in inflammatory pathology (18, 19). We recently
investigated the role of ILC1s in a mouse model of colitis induced
by anti-CD40 injection into Rag-deficient mice. In this model,
IFN-γ is known as the major factor driving wasting disease
and systemic inflammation (67). We find that in this model
of inflammatory bowel disease, intestinal ieILC1s contribute
to intestinal pathology through production of IFN-γ (19).
Similarly, mice with a human immune system show accumulation of IFN-γ-producing human ILC1s in the inflamed intestine
upon challenge with the colitis-inducing agent dextran sodium
sulfate (18, 19).
A recent study by Victorino et al. demonstrated that ILC1s
contribute to organ dysfunction seen in a mouse model of

ischemic kidney injury. The authors of this study identified
NK1.1+ non-T cells as the major culprit that mediate kidney dysfunction following ischemia–reperfusion injury, and found that
depletion with anti-NK1.1, which depletes both cNK cells and
ILC1s in kidneys, ameliorated disease, whereas anti-asialo-GM1
treatment, which preferentially depletes cNK cells, did not protect
from disease (38). The exact mechanism for this ILC1-mediated
tissue damage awaits further investigation.
In contrast to the potential detrimental roles of ILC1s
described above, ILC1s in the salivary gland appear to play
tissue-protective functions during chronic infection. ILC1s at this
tissue site show low ability for IFN-γ production; however, they
can induce cytotoxicity through their expression of TRAIL. Two
recent studies demonstrated that during chronic infection with
murine cytomegalovirus, ILC1s protected from autoimmunity
by regulating both innate and adaptive immune responses in
the salivary gland. In these studies, salivary gland NK1.1+ cells
were shown to preserve gland functions by limiting eosinophil
infiltration and by preventing T cell-mediated autoimmunity
through TRAIL-mediated cytotoxicity toward activated CD4
T cells (35, 68). Although individual roles of cNK cells vs. ILC1s
were not investigated in these studies, a contribution of salivary
gland-resident ILC1s appears likely, in particular in relation to
the observed TRAIL-mediated regulatory roles.

OPEN QUESTIONS
The ILC1 field is still in its infancy, and many questions remain
as to their specific developmental pathways, and to the lineage
relationship between the to-date characterized ILC1s subsets.
For instance, the exact molecular processes that mediate lineage specification of ILC1 vs. cNK cells during the branch point
from αLP to either CHILP or NKP are insufficiently understood.
Furthermore, for several of the putative ILC1 subsets, a lineage
relationship to ILC1s awaits confirmation. Examples of those
subsets include salivary gland ILC1s, uterine ILCs, and subsets of
dermal ILCs. Additional NK-like cells with non-typical phenotype and functions have been described, such as CD127+ blood
and splenic ILC1s and GATA-3-dependent thymic NK cells (13,
45, 69, 70).

ILC1s IN TISSUE INFLAMMATION
AND AUTOIMMUNITY
The production of pro-inflammatory cytokines by group 1 ILCs
has important functions during antimicrobial immune responses.
Frontiers in Immunology | www.frontiersin.org
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Furthermore, to date, the extent of ILC plasticity is not clear.
As discussed above, ILC3s can convert to ILC1-like cells during
inflammatory conditions. A recent study now also provided evidence that a subset of human ILC1s can gain ILC3-like phenotype
and function (24). Further studies will be required to define
whether this ILC1 subset represents a precursor population
that differentiates into ILC3s, or a mature ILC1 population that
undergoes conversion to ILC3s, and to investigate the mechanism
and functional relevance of this ILC1 to ILC3 conversion.
The roles of ILC1s vs. cNK cells during protective host
responses and chronic inflammation are only now starting to
being investigated and there is little evidence of their beneficial
or pathogenic functions during these processes. Group 2 and 3
ILCs play important roles both as initiators of local inflammation, as well as in the resolution of inflammation and restoration

of tissue integrity (71). Further studies are needed to elucidate
the specific contributions of ILC1s in these processes, and to
investigate potential crosstalk between ILC1s with other ILCs and
with adaptive immune cells during the initiation and resolution
of inflammation.
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